# A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors

> **NCT04975204** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 126 (estimated)

## Conditions studied

- Advanced Malignant Tumor

## Interventions

- **DRUG:** TQB3909 Tablets

## Key facts

- **NCT ID:** NCT04975204
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-18
- **Primary completion:** 2022-12
- **Final completion:** 2024-08
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2022-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04975204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04975204, "A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04975204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*